SLC6A3 and Parkinson disease: Although the number of studies on VMAT-2 PET imaging in neurodegenerative disorders such as PD is much smaller than the number of studies on DAT imaging and 18F-FDOPA, the above-mentioned patterns of loss of striatal binding do—generally speaking—match the findings of DAT studies (37–40).